Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant-Reference-Cited by-同舟云学术

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant

Published:2021-05-07 Issue:4 Volume:39 Page:580-583
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Papayannidis Cristina¹^ORCID,Sartor Chiara²^ORCID,Dominietto Alida³,Zappone Elisabetta⁴,Arpinati Mario¹,Marconi Giovanni²⁵^ORCID,Cristiano Gianluca²,Nanni Jacopo²,Parisi Sarah²,Barbato Francesco²,Paolini Stefania¹,Soverini Simona¹²^ORCID,Terragna Carolina¹,Robustelli Valentina²,Testoni Nicoletta¹²,Chirumbolo Gabriella²,Curti Antonio¹,Cavo Michele¹²,Bonifazi Francesca¹

Affiliation:

1. IRCCS Azienda Ospedaliero‐Universitaria di Bologna Istituto di Ematologia “Seràgnoli” Bologna Italy

2. Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università di Bologna Bologna Italy

3. Ematologia e Centro Trapianti IRCCS Ospedale Policlinico San Martino Genova Italy

4. Haematology Unit Policlinico Le Scotte AOUS Siena Italy

5. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola FC Italy

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2886

Reference10 articles.

1. Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

2. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

3. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

4. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia

5. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy;Clinical Case Reports;2023-12

2. Editorial: Novel mechanism and strategies to overcome relapse after allogeneic stem cell transplantation;Frontiers in Immunology;2023-07-11

3. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant;Frontiers in Immunology;2023-07-04

4. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia;Blood Reviews;2023-05

5. Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions;OncoTargets and Therapy;2023-01